FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of pharmaceuticals, namely to an aqueous ophthalmic pharmaceutical composition and its use for the local treatment of eye pain. The composition contains tramadol or its pharmacologically acceptable salt as the sole active ingredient at a concentration of 0.04% wt. / vol. to 0.07% wt. /vol., expressed as an equivalent concentration of tramadol hydrochloride, an isotonant, a pH-regulating substance, and water as the carrier medium.
EFFECT: group of inventions provides a composition with very high efficacy for the local treatment of eye pain with tramadol content in the range of low concentrations of 0.04–0.07% wt. /vol. and in the absence of other active ingredients.
13 cl, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION OF IBUPROFEN AND TRAMADOL FOR OPHTHALMIC APPLICATION | 2014 |
|
RU2694369C2 |
CLOBETAZOLE COMPOSITION IN THE FORM OF OIL-IN-WATER NANO-EMULSION | 2018 |
|
RU2759901C2 |
COMBINED OPHTHALMIC AGENT | 2019 |
|
RU2733392C1 |
STABLE PHARMACEUTICAL COMPOSITION WITH FIXED DOSE, CONTAINING MOMETASONE AND OLOPATADINE | 2014 |
|
RU2687551C2 |
FINAFLOXACIN SUSPENSION COMPOSITIONS | 2013 |
|
RU2693476C2 |
HYALURONIC ACID COMPOSITIONS WITH HIGH-ELASTICITY AND METHODS OF USING THEREOF | 2016 |
|
RU2727809C2 |
INJECTABLE PHARMACEUTICAL COMPOSITION OF DEXKETOPROFEN AND TRAMADOL | 2013 |
|
RU2660356C2 |
SELF-PRESERVED WATER PHARMACEUTICAL COMPOSITIONS | 2007 |
|
RU2436568C2 |
OPHTHALMIC COMPOSITION | 2012 |
|
RU2639472C2 |
OPHTHALMIC COMPOSITIONS WITH IMPROVED DESSICATION PROTECTION AND RETENTION | 2013 |
|
RU2659207C2 |
Authors
Dates
2021-03-11—Published
2016-09-05—Filed